Alzheimer's Disease Trial, Recruiting NCT07306598 Sponsor: Tianjin Medical University Condition: Alzheimer's Disease
Back to Alzheimers Disease

Alzheimer's Disease Trial, Recruiting

NCT07306598
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People between 18 and 90 years old
  • People of any gender
  • People whose clinical results support a diagnosis of neurodegeneration, with no evidence of other neurological diseases
  • Healthy people, or people who have been diagnosed with probable Alzheimer's disease, or dementia caused by other conditions
  • People for whom a signed informed consent form has been provided — either by the person themselves, or by their legal guardian or carer

Who may not be able to join:

  • People with a known allergy to [18F]NIDF or any of its ingredients
  • People who are unable to provide written consent themselves and do not have a legally authorised representative available to provide consent on their behalf
  • People who are unwilling or unable to have a PET scan or the associated tracer injection
  • People with a condition that, in the investigator's opinion, could increase risk, affect their ability to tolerate the study procedures, or interfere with data collection or analysis — for example, kidney or liver failure, or advanced cancer (confirm with trial site)
  • People who have received an experimental drug or device within the past month where the safety or effectiveness is not yet established
  • People who have other serious neurological disorders, or serious conditions affecting the digestive system, heart, liver, kidneys, blood, tumours, hormones, breathing, or immune system
  • People who are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: +8618702292537

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Tianjin Medical University
Registry
ClinicalTrials.gov
Start date
1 November 2025
Est. completion
1 December 2030

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Safety Assessment; The Biodistribution of [18F]NIDF in subjects

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov